Fortunately for growth investors, there are plenty of shares on the Australian share market with strong long term growth potential.
Two such shares are named below. Here’s why analysts are positive on them:
ResMed Inc. (ASX: RMD)
The first ASX growth share to consider is ResMed. It is focused on the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders.
ResMed’s product support suffers of sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other chronic diseases.
Thanks to its world class portfolio, huge (and growing) market opportunity, and wide distribution network, ResMed appears well-placed for growth again over the 2020s. Particularly given a major product recall from a key rival.
Morgans is very positive on ResMed. It believes “the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”
Its analysts currently have an add rating and $40.46 price target on its shares. This is notably higher than the current ResMed share price of $31.83.
Xero Limited (ASX: XRO)
Another ASX growth share to look at is Xero. It is a provider of a cloud-based business and accounting solution to small and medium sized businesses.
Xero has been growing strongly for many years and looks well-placed to continue this trend in the future. This is thanks to its ongoing international expansion, value accretive acquisitions, the transition to the cloud, and its burgeoning app ecosystem. The latter has significant monetisation potential according to the team at Goldman Sachs.
Goldman believes the app ecosystem could support Xero’s ARPU growth in the coming years. Which, combined with subscriber growth, is expected to underpin strong revenue growth over the 2020s.
The broker currently has a buy rating and $158.00 price target on its shares. This compares to the latest Xero share price of $101.67.
The post Analysts name 2 ASX growth shares to buy appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- The ASX 200 is awash with 52-week lows on Friday. Here are some of the biggest names growing smaller
- 3 buy-rated ASX 200 shares
- How did ASX tech shares perform today?
- 3 ASX growth shares to buy after recent market weakness
- Down 24% in 2022: Is the Xero (ASX:XRO) share price a strong buy?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Xero. The Motley Fool Australia owns and has recommended Xero. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/EGyOqVc
Leave a Reply